Lima, C. M. S. P. R., Yothers, G., George, T. J., Hochster, H. S., Sanoff, H. K., Cohen, D. J., Guthrie, K. A., Jacobs, S. A., Saeed, A., Kopetz, S., Colangelo, L. H., Freeman, T., Cole, S. W., Zuckerman, D. S., Hong, T. S., Henry, N. L., Ganz, P. A., Blanke, C. D., Wolmark, N., Overman, M. J. (2026). Colorectal Cancer Metastatic dMMR Immunotherapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo (FFX/bev) in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC)— NRG-GI004/SWOG-S1610.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.2_suppl.14